BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32366787)

  • 1. Primary Neuroendocrine Tumor of the Ileostomy Stoma on 68Ga-DOTATATE PET/CT.
    Yu L; Braun A; Hansen NJ; Downey RT; Johnson CM
    Clin Nucl Med; 2020 Jun; 45(6):463-464. PubMed ID: 32366787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors.
    You H; Kandathil A; Beg M; De Blanche L; Kazmi S; Subramaniam RM
    Nucl Med Commun; 2020 Oct; 41(10):1060-1065. PubMed ID: 32732600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 68Ga-FAPI PET/CT Versus 68Ga-DOTATATE PET/CT in the Evaluation of a Patient With Neuroendocrine Tumor.
    Kömek H; Gündoğan C; Can C
    Clin Nucl Med; 2021 May; 46(5):e290-e292. PubMed ID: 33351508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of somatostatin receptor expressing tumor volume calculated from
    Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine Tumor Diagnosis and Management:
    Sanli Y; Garg I; Kandathil A; Kendi T; Zanetti MJB; Kuyumcu S; Subramaniam RM
    AJR Am J Roentgenol; 2018 Aug; 211(2):267-277. PubMed ID: 29975116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging Characteristics of Coexisting Primary Pulmonary Carcinoid Tumor and Multiple Myeloma on 18F-FDG and 68Ga-DOTATATE PET/CT.
    Lu Y
    Clin Nucl Med; 2019 Nov; 44(11):914-915. PubMed ID: 31306189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
    J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT.
    Ulaner GA; Bodei L
    Clin Nucl Med; 2019 Apr; 44(4):330-331. PubMed ID: 30688738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
    Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
    J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 68Ga-DOTATATE PET/CT Incidentally Detects Relapsed Chronic Lymphocytic Leukemia in Patient With Metastatic Neuroendocrine Tumor.
    Alabed YZ
    Clin Nucl Med; 2023 Feb; 48(2):e78-e79. PubMed ID: 36607378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT "Superscan" in Metastatic Pancreatic Neuroendocrine Tumor.
    Chan M; Schembri GP
    Clin Nucl Med; 2017 Feb; 42(2):108-109. PubMed ID: 27997429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence of the Redifferentiation-Akin Phenomenon on
    Sharma P; Basu S
    J Nucl Med Technol; 2020 Sep; 48(3):290-291. PubMed ID: 32111657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 68Ga DOTATATE PET/CT of Non-FDG-Avid Pulmonary Metastatic Hemangiopericytoma.
    Hung TJ; Macdonald W; Muir T; Celliers L; Al-Ogaili Z
    Clin Nucl Med; 2016 Oct; 41(10):779-80. PubMed ID: 27454598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice.
    Aalbersberg EA; Geluk-Jonker MM; Young-Mylvaganan T; de Wit-van der Veen LJ; Stokkel MPM
    J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. False-Positive Uptake in Splenic Hemangioma on 68 Ga-DOTATATE PET/CT.
    Zhu B; Yoon E; Mahajan S; Kranz AO
    Clin Nucl Med; 2023 Jun; 48(6):518-519. PubMed ID: 37075248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.